COMMUNIQUÉS West-GlobeNewswire

Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019
06/05/2019
MENLO PARK, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
06/05/2019
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new [...]
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
06/05/2019
BELBUCA ® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 Million Symproic ® Acquisition and Commercial Integration Successfully Completed Company Raises Full-Year BELBUCA Net Sales Expectations [...]
ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
06/05/2019
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- [...]
Profound Medical Announces First Quarter 2019 Financial Results
06/05/2019
- Receives Notification of FDA Acceptance of 510(k) Application Filing for TULSA-PRO® - TORONTO, May 06, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only [...]
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
06/05/2019
- Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 - CARLSBAD, Calif [...]
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019
06/05/2019
- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30 p.m. EDT - CARLSBAD, Calif., May 06, 2019 [...]
Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
06/05/2019
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States NOVATO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ [...]
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
06/05/2019
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and Webcast Scheduled Today [...]
Geocann Launches Cannabidiol (CBD) Soft Gel Formulations Utilizing Patented Drug Delivery Technology
06/05/2019
Condition-specific portfolio showcases cannabis industry first-to-market milestones, including clinically measured bioavailability and science-backed cannabinoid and terpene ratios FORT COLLINS, Colo., May 06, 2019 ( [...]
Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
06/05/2019
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of [...]
ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019
06/05/2019
Conference call and webcast on Tuesday, May 7 at 2:30 pm CET/8:30 am EDT TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new manufacturing site [...]
ERYTECH publie ses résultats financiers et fait le point sur ses activités du premier trimestre 2019
06/05/2019
Conférence téléphonique et webcast mardi 7 mai à 14h30 (heure de Paris) Recrutement en cours dans l’étude TRYbeCA1 de phase 3 avec eryaspase dans le traitement en seconde ligne du cancer du pancréas Achèvement de la [...]
Pharmaceutical Giant, Quinton C Oswald: Nominee For Florida's Medical Award
06/05/2019
Vero Beach, Florida, May 06, 2019 (GLOBE NEWSWIRE) -- Mr. Quinton Charles Oswald, one of Florida's finest, has been nominated for the State's 2019 Medical Award. Quinton Oswald Vero Beach Florida, is a luminary in the [...]
Tauriga Sciences Inc. to Present at the 9th Annual LD Micro Invitational Conference on June 5, 2019 at the Luxe Sunset Hotel (Bel Air, California)
06/05/2019
Los Angeles, CA, May 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, [...]
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
06/05/2019
Positive Findings from Expanded Access Trial in a Patient with Late Onset Tay Sachs (LOTS) LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of [...]
HealthEC CIO Sita Kapoor Receives Health Data Management's 2019 Most Powerful Women in Healthcare IT Award
06/05/2019
Cited for the second consecutive year, Kapoor recognized for her leadership as a healthcare IT vendor executive EDISON, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- HealthEC, LLC , a 2019 Best in KLAS provider of population [...]
Annual General Meeting of Infant Bacterial Therapeutics
06/05/2019
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 6, 2019, among other things, the following was resolved: determination of the annual report discharge granted to board members and the CEO [...]
Ossur Hf : Transactions in relation to share buyback program
06/05/2019
Announcement no. 29/2019 6 May 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]

Pages